The briefing
At ACAAI 2026, a 64-patient cohort with alpha-gal syndrome reported no need for epinephrine for food reactions during omalizumab therapy. The findings suggest potential benefit but call for further study.
Original headline
Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome